IO Informatics Sentient Suite Expands into Precision Medicine
News Dec 04, 2012
IO Informatics announced today IO Healthcare, an extension of the company's award winning life sciences platform, Sentient, into precision medicine applications including biomarker discovery, clinical trial optimization and decision support. By adding clinical, genomic, metabolic and proteomic information to the platform's existing repository of public resources, IO Healthcare enables the earlier application of clinical information to enhance research and development.
"Since 2003, IO has been addressing research informatics needs at pharmaceutical and biotech companies with our semantic technology platform," said Robert Stanley, IO Informatics President and Chief Executive Officer. "Now, with IO Healthcare, we directly address the challenges of taking molecular data into clinical applications to realize the promise of precision medicine.” Stanley added, "With the growing availability and decreasing cost to integrate and query data from genomics and other molecular biology and clinical applications, IO Healthcare is a natural extension for both our Sentient platform and our customers, who have been using IO in their research for many years."
The Company’s semantic framework makes it possible to apply patterns including content from patient records and phenotypic information such as gene, protein and metabolic variables relevant across all stages of research, from early stage experimentation to precision medicine.
Stanley went on to say, “We are also very happy to have Bill Hayden join us to spearhead our Healthcare effort. Bill was previously with IO from 2007-2009, where he was instrumental in creating collaborations between IO and worldwide centers of excellence.”
"I am happy to work with IO at a very exciting time for both the company and the healthcare industry. It is a time where promise becomes practice. We have heard a lot over the years of the hope of true precision medicine. With advances in science and technology, that dream is now becoming a reality. IO sits on the crest of what I believe will be a new way and approach of delivering focused treatments and cures for a variety of diseases,” said Hayden.
Hayden went on to say, “IO recently announced details of its partnership with the PROOF Centre of Excellence (Vancouver, BC) where they have successfully married the identification of relevant biomarkers and related data from PROOF Centre with Sentient to produce valuable Applied Semantic Knowledgebases (ASK) that will be used in the clinic to help identify and segment patients affected by major organ failure. Dr. Bruce McManus, Director of the PROOF Centre stated, “This collaborative project represents a major step forward to realizing the promise of biomarker-based screening for precision medicine and better healthcare at lower cost.” The resulting application from the IO - PROOF Centre collaboration is scheduled to be launched in the clinic in 2013.”
In addition, pharmaceutical & biotech companies can use the IO Healthcare platform to accelerate drug discovery by applying human biology earlier in the discovery process, to discover and develop predictive biomarkers, and to optimize clinical trial design and patient selection to reduce development timelines and increase the chance of successful approval for new therapies.
Agent Reverses Resistance to Targeted Drug in Some LeukemiasNews
After discovering how some hematologic cancer cells manage to elude death from a targeted therapy, Dana-Farber Cancer Institute scientists have double-crossed the cancer cells with a drug that renders them vulnerable to the targeted agent.READ MORE
Metabolomic Profiling Identifies Taurine as New MS TherapeuticNews
New research suggests that administering taurine, a molecule naturally produced by human cells, could boost the effectiveness of current multiple sclerosis (MS) therapies. The discovery also highlights the potential for a technique called “metabolomic profiling,” which can identify useful endogenous metabolites the body already makes in small quantities, such as taurine, for new applications in drug therapies.READ MORE
Immune Response Restored in Patients with Melanoma Thanks to New CompoundNews
A novel compound may restore immune response in patients with melanoma, according to a study presented at the ESMO Immuno Oncology Congress 2017.READ MORE